Treats clinically important hypotension resulting primarily from vasodilation in the…. ANDA 211081, held by Milla Pharms. Phenylephrine Hydrochloride.
As of Nov 16, 2026, ANDA 211081 (Phenylephrine Hydrochloride), held by Milla Pharms, was first approved by FDA on Jul 17, 2020, with 0 approved supplements and 0 published complete response letters.
Phenylephrine hydrochloride Injection, 10 mg/mL is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 17, 2020 | Original application | Approved | None posted |
| Phenylephrine Hydrochloride10MG/ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
| Phenylephrine Hydrochloride50MG/5ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
| Phenylephrine Hydrochloride100MG/10ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters